Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection

Antimicrobial Agents and Chemotherapy
A LepakD Andes

Abstract

Candida auris is an emerging multidrug-resistant threat. The pharmacodynamics of three antifungal classes against nine C. auris strains was explored using a murine invasive candidiasis model. The total drug median pharmacodynamic (PD) target associated with net stasis was a fluconazole AUC/MIC (the area under the concentration-time curve over 24 h in the steady state divided by the MIC) of 26, an amphotericin B Cmax/MIC (maximum concentration of drug in serum divided by the MIC) of 0.9, and a micafungin AUC/MIC of 54. The micafungin PD targets for C. auris were ≥20-fold lower than those of other Candida species in this animal model. Clinically relevant micafungin exposures produced the most killing among the three classes.

References

Feb 10, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
Feb 22, 2001·Antimicrobial Agents and Chemotherapy·D AndesR Conklin
Apr 14, 2010·Antimicrobial Agents and Chemotherapy·D AndesA Lepak
Dec 15, 2010·Critical Care Clinics·Alexander Lepak, David Andes
Jul 1, 2011·Journal of Clinical Microbiology·Wee Gyo LeeHee-Chang Jang
Sep 21, 2013·Emerging Infectious Diseases·Anuradha ChowdharyJacques F Meis
Dec 21, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A ChowdharyJ F Meis
Jun 26, 2014·Emerging Infectious Diseases·Rindidzani E MagoboNelesh P Govender
Nov 12, 2014·Cold Spring Harbor Perspectives in Medicine·Alexander J Lepak, David R Andes
May 20, 2015·Emerging Infectious Diseases·Maha EmaraRitu Bafna
Nov 10, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Anupam PrakashAnuradha Chowdhary
Jul 28, 2016·The Journal of Infection·Belinda CalvoArnaldo Lopes Colombo
Oct 26, 2016·Antimicrobial Resistance and Infection Control·Silke SchelenzMatthew C Fisher
Nov 9, 2016·BMJ : British Medical Journal·Michael McCarthy
Dec 17, 2016·Emerging Infectious Diseases·Soraya E Morales-LópezJosé Y Rodríguez
Dec 19, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shawn R LockhartAnastasia P Litvintseva
Jan 19, 2017·Emerging Infectious Diseases·Ronen Ben-AmiTalya Finn
Jan 19, 2017·Emerging Infectious Diseases·Leighann SherryRiina Rautemaa-Richardson
Jan 31, 2017·Revista iberoamericana de micología·Alba Cecilia Ruiz GaitánJavier Pemán
Feb 17, 2017·Medical Mycology·Andrew M BormanElizabeth M Johnson

❮ Previous
Next ❯

Citations

Apr 11, 2018·Antimicrobial Agents and Chemotherapy·Milena KordalewskaDavid S Perlin
Nov 17, 2017·Clinical Microbiology Reviews·Anna Jeffery-SmithColin S Brown
Dec 12, 2018·Antimicrobial Agents and Chemotherapy·Nathan P WiederholdThomas F Patterson
May 14, 2019·The Journal of Antimicrobial Chemotherapy·Catiana DudiukGuillermo Garcia-Effron
May 23, 2019·Journal of Occupational and Environmental Hygiene·Steven R TorresMagdia De Jesus
Feb 19, 2019·Mycoses·Shabir A Lone, Aijaz Ahmad
Jun 22, 2019·The Journal of Antimicrobial Chemotherapy·Sebastian WursterDimitrios P Kontoyiannis
Aug 8, 2017·Expert Review of Anti-infective Therapy·Bhagyashri D NavalkelePranatharthi Chandrasekar
Mar 1, 2020·Journal of Fungi·Ryan KeanGordon Ramage
Sep 6, 2018·Antimicrobial Agents and Chemotherapy·Alexander J LepakDavid R Andes
Feb 2, 2018·The Journal of Infectious Diseases·Frederic Lamoth, Dimitrios P Kontoyiannis
Aug 8, 2018·Medical Mycology·Kaitlin ForsbergSnigdha Vallabhaneni
Aug 20, 2019·Internal Medicine Journal·Chong W OngUNKNOWN Australian and New Zealand Mycoses Interest Group (ANZMIG); and the Healthcare Infection Control Special Interest Group (HIC
Feb 13, 2020·Revista Da Sociedade Brasileira De Medicina Tropical·Leticia Aparecida SchiaveRoberto Martinez
Mar 17, 2018·Archives of Disease in Childhood·Adilia Warris
May 1, 2020·Clinical Microbiology Reviews·Elizabeth L BerkowLuis Ostrosky-Zeichner
Feb 9, 2021·Clinical Pharmacology and Therapeutics·Craig R RaynerKaren Rowland-Yeo
Jun 29, 2021·Expert Review of Clinical Pharmacology·Daniele R GiacobbeMatteo Bassetti
Jun 29, 2021·Curēus·Mais B AlashqarSami Almustanyir

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.